<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543877</url>
  </required_header>
  <id_info>
    <org_study_id>FL113</org_study_id>
    <nct_id>NCT04543877</nct_id>
  </id_info>
  <brief_title>WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study</brief_title>
  <official_title>WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>USDA, Western Human Nutrition Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>USDA, Western Human Nutrition Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if adding dietary fiber, such as inulin, to a diet&#xD;
      that does not have enough fiber would raise the levels of potentially beneficial bacteria,&#xD;
      such as Bifidobacterium, in the gut. There is evidence to suggest that these microbes can&#xD;
      affect gut health and immune response, including to vaccines. The investigators will examine&#xD;
      how inulin in the diet (compared to the maltodextrin control) (1) causes changes in the&#xD;
      composition and function of the gut microbes, (2) reduces gut inflammation and gut leakiness&#xD;
      caused by the vaccine, and (3) increases immune response to vaccination. Intestinal and&#xD;
      whole-body responses will be measured in all participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inulin, a dietary fiber supplement, is known to increase gut levels of potentially beneficial&#xD;
      bacteria, including Bifidobacterium that are indigenous to gut microbiomes. Our underlying&#xD;
      hypothesis is that the commensal microbiome, including Bifidobacterium, in the proximal colon&#xD;
      or distal ileum affects the environment of draining lymph nodes and can thus modulate immune&#xD;
      responses, including to vaccines. In the current study, participants will consume 12&#xD;
      grams/day inulin or maltodextrin (control) for 4 weeks before the administration of the Ty21a&#xD;
      typhoid fever vaccine, 1 week during the vaccine, and 1 week after the vaccine. Vaccine&#xD;
      response will be measured by quantitating T cells and IgG- or IgA-secreting plasma cells&#xD;
      specific for Ty21a. Gut permeability will be measured before and after the inulin&#xD;
      intervention, before and after the vaccine administration, and at the end of the study.&#xD;
      Systemic inflammation and immune activation will be measured by analyzing blood for markers&#xD;
      of inflammation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2022</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in antibody response to typhoid vaccination</measure>
    <time_frame>Day 36, 47, 54, and 124</time_frame>
    <description>Measurement of baseline level (Day 36; before first vaccine dose) and change of Ty21a vaccine-specific immunoglobulin G (IgG) and immunoglobulin A (IgA) using peripheral blood mononuclear cells (PBMC) for the antibody in lymphocyte supernatant (ALS) assay as an indicator of plasma cell development.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fecal antibody levels from typhoid vaccination</measure>
    <time_frame>Day 36, 47, 54, and 124</time_frame>
    <description>Measurement of baseline level (Day 36; before first vaccine dose) and change of Ty21a vaccine-specific IgG and IgA in fecal extract using an enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in T-cell response to typhoid vaccination</measure>
    <time_frame>Day 36, 47, 54 and 124</time_frame>
    <description>Measurement of baseline level (Day 36; before first vaccine dose) and change of Ty21a vaccine-specific cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T-cells in PBMC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fecal microbiome</measure>
    <time_frame>Day 7, 35, 46, 53, and 123</time_frame>
    <description>Measurement of relative abundance of colonic bacteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of inflammation</measure>
    <time_frame>Day 8, 36, 47, 49, 54, and 124</time_frame>
    <description>Measurement of plasma cytokines, chemokines, and acute phase proteins using a multiplex immunoassay panel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal myeloperoxidase</measure>
    <time_frame>Day 7, 35, 46, 53, and 123</time_frame>
    <description>Measurement of myeloperoxidase, a marker of inflammation, in stool using an ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal neopterin</measure>
    <time_frame>Day 7, 35, 46, 53, and 123</time_frame>
    <description>Measurement of neopterin, a marker of inflammation, in stool using an ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary lactulose</measure>
    <time_frame>Day 8, 36, 47, 54, and 124</time_frame>
    <description>Measurement of lactulose, a synthetic sugar and an indicator of intestinal permeability, in urine by gas chromatography mass-spectrometry (GC-MS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary D-mannitol</measure>
    <time_frame>Day 8, 36, 47, 54, and 124</time_frame>
    <description>Measurement of D-mannitol, a sugar alcohol and an indicator of intestinal permeability, in urine by GC-MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary sucralose</measure>
    <time_frame>Day 8, 36, 47, 54, and 124</time_frame>
    <description>Measurement of sucralose, an artificial sweetener and an indicator of intestinal permeability, in urine by GC-MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma intestinal fatty acid binding protein</measure>
    <time_frame>Day 8, 36, 47, 54, and 124</time_frame>
    <description>Measurement of intestinal fatty acid binding protein, an indicator of intestinal dysfunction, in plasma using an ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma D-lactate</measure>
    <time_frame>Day 8, 36, 47, 54, and 124</time_frame>
    <description>Measurement of D-lactate, an indicator of intestinal permeability, in plasma using an ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma citrulline</measure>
    <time_frame>Day 8, 36, 47, 54, and 124</time_frame>
    <description>Measurement of citrulline, an indicator of intestinal permeability, in plasma using an ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma diamine oxidase</measure>
    <time_frame>Day 8, 36, 47, 54, and 124</time_frame>
    <description>Measurement of diamine oxidase, an indicator of intestinal integrity, in plasma using an ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in marker of lipopolysaccharide (LPS) exposure</measure>
    <time_frame>Day 8, 36, 47, 54, and 124</time_frame>
    <description>Measurement of plasma LPS-binding protein using an ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline dietary fiber intake</measure>
    <time_frame>Pre-study</time_frame>
    <description>Assessment of dietary fiber that is consumed by a food frequency questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in dietary intake</measure>
    <time_frame>Period 1: Days 1-7; Period 2: Days 26-35; Period 3: Days 116-123</time_frame>
    <description>Three non-consecutive 24-hour dietary recalls will be collected per period. A 3-day average of nutrient intake will be calculated per period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stool consistency</measure>
    <time_frame>Period 1: Days 1-7; Period 2: Days 26-35; Period 3: Days 36-46; Period 4: Days 47-53; Period 5: Days 116-123</time_frame>
    <description>Measurement of stool consistency using the Bristol stool scale, a medical tool used to classify stool forms into 7 categories. Stools will be collected 3 times per period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Inflammation</condition>
  <condition>Vaccine</condition>
  <condition>Intestinal Permeability</condition>
  <condition>Typhoid Fever</condition>
  <arm_group>
    <arm_group_label>Inulin and Ty21a Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will consume 12 grams/day of inulin for 4 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maltodextrin and Ty21a Vaccine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will consume 12 grams/day of maltodextrin (control) for 4 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inulin</intervention_name>
    <description>Consume 12 grams/day of inulin for 6 weeks (Day 9 - 53).</description>
    <arm_group_label>Inulin and Ty21a Vaccine</arm_group_label>
    <other_name>Orafti GR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Consume 12 grams/day of maltodextrin for 6 weeks (Day 9 - 53).</description>
    <arm_group_label>Maltodextrin and Ty21a Vaccine</arm_group_label>
    <other_name>Maltrin M100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ty21a Typhoid Fever Vaccine</intervention_name>
    <description>All participants will receive the vaccine. One capsule is swallowed on alternate days, e.g. days 40, 42, 44, and 46 for a total of 4 capsules.</description>
    <arm_group_label>Inulin and Ty21a Vaccine</arm_group_label>
    <arm_group_label>Maltodextrin and Ty21a Vaccine</arm_group_label>
    <other_name>Vivotif</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body Mass Index (BMI) 18.5 - 39.9 kg/m2&#xD;
&#xD;
          2. inadequate total dietary fiber intake (&lt;14 g/1000 kcal/day)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. blood pressure greater than or equal to 140/90 mmHg&#xD;
&#xD;
          2. has HIV/AIDS or another disease that affects the immune system&#xD;
&#xD;
          3. has any kind of cancer&#xD;
&#xD;
          4. inability to lift 30 pounds with assistance (for transporting refrigerated stool&#xD;
             containers)&#xD;
&#xD;
          5. decline to take an HIV blood test&#xD;
&#xD;
          6. pregnant or lactating women&#xD;
&#xD;
          7. refusal to take a pregnancy test&#xD;
&#xD;
          8. female subjects: refusal to use a method of birth control 1 week prior to the&#xD;
             administration of the vaccine, 1 week during the vaccine, and 1 week after the vaccine&#xD;
&#xD;
          9. allergy to vaccine components, i.e. thimerosal and enteric-coated capsules&#xD;
&#xD;
         10. allergy to oral typhoid vaccine&#xD;
&#xD;
         11. use of anti-inflammatory medications, i.e. nonsteroidal anti-inflammatory drugs&#xD;
             (NSAID), aspirin, 3 or more times per month&#xD;
&#xD;
         12. use of sulfonamides or antibiotics 1 week prior to the receipt of Ty21a vaccine.&#xD;
&#xD;
         13. use of anti-hypertensive drugs, i.e. beta blockers, diuretics, calcium channel&#xD;
             blockers&#xD;
&#xD;
         14. use of anti-malaria drugs, i.e. mefloquine, chloroquine, and proguanil&#xD;
&#xD;
         15. use of drugs that affects the immune system, i.e. immunosuppressants, immune-modifying&#xD;
             drugs, corticosteroids, i.e. cortisone, prednisone, methylprednisolone, for 2 weeks or&#xD;
             longer&#xD;
&#xD;
         16. use of biologics, i.e. Lantus, Remicade, Rituxan, Humira, Herceptin, Avastin,&#xD;
             Lucentis, Enbrel for 2 weeks or longer&#xD;
&#xD;
         17. undergoing cancer treatment with radiation or drugs&#xD;
&#xD;
         18. greater than 10 years residence in a typhoid-endemic area&#xD;
&#xD;
         19. receipt of typhoid vaccine in the last 5 years&#xD;
&#xD;
         20. receipt of any vaccine two weeks prior to receipt of Ty21a vaccine&#xD;
&#xD;
         21. individuals at increased risk of developing complications from a live, bacterial&#xD;
             vaccine&#xD;
&#xD;
         22. history of typhoid fever&#xD;
&#xD;
         23. history of primary immune deficiency or autoimmune disease&#xD;
&#xD;
         24. history of acute or chronic gastrointestinal (GI) disorder, i.e. Crohn's disease,&#xD;
             irritable bowel syndrome, gastric ulcer&#xD;
&#xD;
         25. diarrheal illness (defined as passing 3 or more abnormally loose or watery stool in a&#xD;
             24 hour period) or persistent vomiting 2 weeks prior to the study&#xD;
&#xD;
         26. history of chronic illnesses, i.e. diabetes, cardiovascular disease, cancer,&#xD;
             gastrointestinal malabsorption or inflammatory diseases, kidney disease, autoimmune&#xD;
             disorders, HIV, liver disease, including hepatitis B and C&#xD;
&#xD;
         27. asthma if taking medication on a daily basis&#xD;
&#xD;
         28. recent surgery (within 3 months)&#xD;
&#xD;
         29. history of GI surgery&#xD;
&#xD;
         30. recent hospitalization (within 3 months)&#xD;
&#xD;
         31. fever (within 2 weeks)&#xD;
&#xD;
         32. unwillingness to discontinue consumption of artificial sweeteners in foods or drinks,&#xD;
             i.e. sport drinks, coconut water, &quot;diet&quot; drinks and foods (possibly containing&#xD;
             sucralose)&#xD;
&#xD;
         33. unwillingness to discontinue probiotic, prebiotic, or other supplements (except&#xD;
             Recommended Dietary Allowance-level vitamin and mineral supplements), fiber&#xD;
             supplements, or food and beverage products containing inulin, chicory root fiber, or&#xD;
             maltodextrin during the study&#xD;
&#xD;
         34. not having at least one arm vein suitable for blood drawing&#xD;
&#xD;
         35. unwilling or uncomfortable with blood draws and 24-hour urine and stool collection&#xD;
&#xD;
         36. regular blood or blood product donation and refusal to suspend donation&#xD;
&#xD;
         37. current participation in another research study&#xD;
&#xD;
         38. unable to fast for 12-16 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danielle Lemay, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USDA, ARS, Western Human Nutrition Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Stephensen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USDA, ARS, Western Human Nutrition Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Kable, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USDA, ARS, Western Human Nutrition Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Bonnel, PhD</last_name>
    <phone>530-752-4184</phone>
    <email>ellen.bonnel@usda.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuriko Adkins, PhD</last_name>
    <phone>530-752-9469</phone>
    <email>yuriko.adkins@usda.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USDA, ARS, Western Human Nutrition Research Center</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ellen Bonnel, PhD</last_name>
      <phone>530-752-4184</phone>
      <email>ellen.bonnel@usda.gov</email>
    </contact>
    <contact_backup>
      <last_name>Yuriko Adkins, PhD</last_name>
      <phone>530-752-9469</phone>
      <email>yuriko.adkins@usda.gov</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Meyer D, Stasse-Wolthuis M. The bifidogenic effect of inulin and oligofructose and its consequences for gut health. Eur J Clin Nutr. 2009 Nov;63(11):1277-89. doi: 10.1038/ejcn.2009.64. Epub 2009 Aug 19. Review.</citation>
    <PMID>19690573</PMID>
  </reference>
  <reference>
    <citation>Costabile A, Kolida S, Klinder A, Gietl E, Bäuerlein M, Frohberg C, Landschütze V, Gibson GR. A double-blind, placebo-controlled, cross-over study to establish the bifidogenic effect of a very-long-chain inulin extracted from globe artichoke (Cynara scolymus) in healthy human subjects. Br J Nutr. 2010 Oct;104(7):1007-17. doi: 10.1017/S0007114510001571. Epub 2010 Jul 1.</citation>
    <PMID>20591206</PMID>
  </reference>
  <reference>
    <citation>Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, Bindels LB, de Vos WM, Gibson GR, Thissen JP, Delzenne NM. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut. 2013 Aug;62(8):1112-21. doi: 10.1136/gutjnl-2012-303304. Epub 2012 Nov 7.</citation>
    <PMID>23135760</PMID>
  </reference>
  <reference>
    <citation>Holscher HD, Bauer LL, Gourineni V, Pelkman CL, Fahey GC Jr, Swanson KS. Agave Inulin Supplementation Affects the Fecal Microbiota of Healthy Adults Participating in a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J Nutr. 2015 Sep;145(9):2025-32. doi: 10.3945/jn.115.217331. Epub 2015 Jul 22.</citation>
    <PMID>26203099</PMID>
  </reference>
  <reference>
    <citation>Kolida S, Meyer D, Gibson GR. A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans. Eur J Clin Nutr. 2007 Oct;61(10):1189-95. Epub 2007 Jan 31.</citation>
    <PMID>17268410</PMID>
  </reference>
  <reference>
    <citation>Menne E, Guggenbuhl N, Roberfroid M. Fn-type chicory inulin hydrolysate has a prebiotic effect in humans. J Nutr. 2000 May;130(5):1197-9.</citation>
    <PMID>10801918</PMID>
  </reference>
  <reference>
    <citation>Micka A, Siepelmeyer A, Holz A, Theis S, Schön C. Effect of consumption of chicory inulin on bowel function in healthy subjects with constipation: a randomized, double-blind, placebo-controlled trial. Int J Food Sci Nutr. 2017 Feb;68(1):82-89. doi: 10.1080/09637486.2016.1212819. Epub 2016 Aug 5.</citation>
    <PMID>27492975</PMID>
  </reference>
  <reference>
    <citation>Petry N, Egli I, Chassard C, Lacroix C, Hurrell R. Inulin modifies the bifidobacteria population, fecal lactate concentration, and fecal pH but does not influence iron absorption in women with low iron status. Am J Clin Nutr. 2012 Aug;96(2):325-31. doi: 10.3945/ajcn.112.035717. Epub 2012 Jun 27.</citation>
    <PMID>22743314</PMID>
  </reference>
  <reference>
    <citation>Huda MN, Lewis Z, Kalanetra KM, Rashid M, Ahmad SM, Raqib R, Qadri F, Underwood MA, Mills DA, Stephensen CB. Stool microbiota and vaccine responses of infants. Pediatrics. 2014 Aug;134(2):e362-72. doi: 10.1542/peds.2013-3937. Epub 2014 Jul 7.</citation>
    <PMID>25002669</PMID>
  </reference>
  <reference>
    <citation>Huda MN, Ahmad SM, Alam MJ, Khanam A, Kalanetra KM, Taft DH, Raqib R, Underwood MA, Mills DA, Stephensen CB. Bifidobacterium Abundance in Early Infancy and Vaccine Response at 2 Years of Age. Pediatrics. 2019 Feb;143(2). pii: e20181489. doi: 10.1542/peds.2018-1489.</citation>
    <PMID>30674610</PMID>
  </reference>
  <reference>
    <citation>Zuckerman JN, Hatz C, Kantele A. Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines. Expert Rev Vaccines. 2017 Oct;16(10):1029-1043. doi: 10.1080/14760584.2017.1374861. Review.</citation>
    <PMID>28856924</PMID>
  </reference>
  <reference>
    <citation>Fiorentino M, Lammers KM, Levine MM, Sztein MB, Fasano A. In vitro Intestinal Mucosal Epithelial Responses to Wild-Type Salmonella Typhi and Attenuated Typhoid Vaccines. Front Immunol. 2013 Feb 12;4:17. doi: 10.3389/fimmu.2013.00017. eCollection 2013.</citation>
    <PMID>23408152</PMID>
  </reference>
  <reference>
    <citation>Salerno-Gonçalves R, Galen JE, Levine MM, Fasano A, Sztein MB. Manipulation of Salmonella Typhi Gene Expression Impacts Innate Cell Responses in the Human Intestinal Mucosa. Front Immunol. 2018 Nov 1;9:2543. doi: 10.3389/fimmu.2018.02543. eCollection 2018.</citation>
    <PMID>30443257</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal Health</keyword>
  <keyword>Intestinal Permeability</keyword>
  <keyword>Vaccine Response</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Ty21a Typhoid Vaccine</keyword>
  <keyword>Typhoid Fever</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Bifidobacterium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhoid Fever</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

